Related Experiment Video
Updated: May 5, 2026
Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
Published on: May 16, 2020
Study of antitumor activity of antibodies to TNF-α on Walker carcinosarcoma model
E I Yurlova1, S G Krylova, J L Dugina
1Institute of Pharmacology, Siberian Division of the Russian Academy of Medical Sciences, Tomsk; Materia Medica Holding, Moscow, Russia. JurlovaEI@materiamedica.ru.
Abstract:
The effect of release-active antibodies to TNF-α (Artrofoon) on the development of Walker carcinosarcoma 256 was studied in Wistar rats. Intragastric dose of this drug significantly inhibited the growth of tumor node (55% inhibition of tumor growth), but less effectively than the reference drug cyclophosphamide (80%). The studied drug significantly prolonged animal' lifespan (+97%) and its efficiency in this respect was comparable to that of cyclophosphamide (+96%).
Insights
Release-active antibodies to tumor necrosis factor-alpha (TNF-α) showed significant tumor growth inhibition and prolonged survival in rats with Walker carcinosarcoma 256. Its lifespan extension effect was comparable to cyclophosphamide.
Area of Science:
- Immunology
- Oncology
- Pharmacology
Background:
- Tumor necrosis factor-alpha (TNF-α) plays a critical role in tumor development and progression.
- Targeting TNF-α is a potential therapeutic strategy for cancer treatment.
Purpose of the Study:
- To evaluate the efficacy of release-active antibodies to TNF-α (Artrofoon) in a rat model of Walker carcinosarcoma 256.
- To compare the anti-tumor effects of Artrofoon with cyclophosphamide, a known chemotherapeutic agent.
Main Methods:
- Walker carcinosarcoma 256 was induced in Wistar rats.
- Rats were treated with intragastric doses of Artrofoon or cyclophosphamide.
- Tumor growth inhibition and animal survival rates were assessed.
Main Results:
- Artrofoon significantly inhibited tumor growth by 55%, while cyclophosphamide achieved 80% inhibition.
- Artrofoon significantly prolonged animal lifespan by 97%, comparable to cyclophosphamide's 96% increase.
- Artrofoon demonstrated notable anti-cancer activity and survival benefits.
Conclusions:
- Release-active antibodies to TNF-α (Artrofoon) exhibit significant anti-tumor properties against Walker carcinosarcoma 256.
- Artrofoon offers a promising therapeutic approach with comparable survival benefits to cyclophosphamide.
- Further investigation into TNF-α targeted therapies is warranted for cancer treatment.
